Alvaro Rojas

Santiago, RM, Chile

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity.

A booster dose of an inactivated SARS-CoV-2 vaccine targeting virus variants sustains protective humoral and cellular immunity.

Journal: BMC medicine

Published: April 23, 2025

Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine.

Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine.

Journal: iScience

Published: February 14, 2025

Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.

Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial.

Journal: Nature communications

Published: January 27, 2025

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.

Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.

Journal: EBioMedicine

Published: December 19, 2022

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.

Journal: mBio

Published: August 10, 2022

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.

Journal: eLife

Published: June 29, 2022

Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial.

Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial.

Journal: Vaccines

Published: May 27, 2022

Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort.

Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort.

Journal: Antibiotics (Basel, Switzerland)

Published: April 21, 2022

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.

Journal: Frontiers in immunology

Published: July 16, 2021

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: April 26, 2021

Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.

Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: January 09, 2019

Evaluation of susceptibility and response to therapy with piperacillin-tazobactam in patients with infections caused by Escherichia coli with extended-spectrum β-lactamase (ESBL) CTX-M

Evaluation of susceptibility and response to therapy with piperacillin-tazobactam in patients with infections caused by Escherichia coli with extended-spectrum β-lactamase (ESBL) CTX-M

Journal: Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia

Published: June 14, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026